Relay Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, or a Rule 10b5-1 trading arrangement. No other officers or directors adopted, materially modified, orterminated a Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement during the quarterly period covered by this report.
| Name (Title) | Action Taken(Date of Action) | Type of Trading Arrangement | Expiration Date | Aggregate Number of Securities |
|---|---|---|---|---|
| Donald A. Bergstrom(President, Research and Development) | Adoption(08/08/2024) | Rule 10b5-1 trading arrangement | The earlier of (i) 06/06/2025 and (ii) the execution or expiration of all trade instructions thereunder | Up to 276,000 shares |
| Brian Adams(Chief Legal Officer) | Adoption(08/06/2024) | Rule 10b5-1 trading arrangement | The earlier of (i) 03/31/2025 and (ii) the execution or expiration of all trade instructions thereunder | Up to 20,565 shares |
| Patel Family Irrevocable Trust of 2019 (1) | Adoption (08/07/2024) | Rule 10b5-1 trading arrangement | The earlier of (i) 01/23/2025 and (ii) the execution or expiration of all trade instructions thereunder | Up to 600,000 shares |
(1) This 10b5-1 plan was entered into by an irrevocable trust, which holds the applicable shares for the benefit of Sanjiv K. Patel's family members. Sanjiv K. Patel is our Chief Executive Officer. An independent trustee is trustee of the trust.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.